About Portola Pharmaceuticals (NASDAQ:PTLA)
Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio-11.162037037037
Forward P/E Ratio-9.76
Sales & Book Value
Annual Sales$35.50 million
Price / Sales88.63
Price / CashN/A
Book Value$3.41 per share
Price / Book14.14
Return on Equity-110.46%
Return on Assets-61.18%
Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions
What is Portola Pharmaceuticals' stock symbol?
Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."
How were Portola Pharmaceuticals' earnings last quarter?
Portola Pharmaceuticals Inc (NASDAQ:PTLA) issued its earnings results on Monday, November, 6th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.08. The biopharmaceutical company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $4.71 million. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. The business's revenue was down 58.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.64) earnings per share. View Portola Pharmaceuticals' Earnings History.
When will Portola Pharmaceuticals make its next earnings announcement?
Where is Portola Pharmaceuticals' stock going? Where will Portola Pharmaceuticals' stock price be in 2018?
8 brokers have issued twelve-month price targets for Portola Pharmaceuticals' shares. Their predictions range from $70.00 to $81.00. On average, they expect Portola Pharmaceuticals' share price to reach $75.00 in the next twelve months. View Analyst Ratings for Portola Pharmaceuticals.
What are Wall Street analysts saying about Portola Pharmaceuticals stock?
Here are some recent quotes from research analysts about Portola Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (2/13/2018)
- 2. Cowen Inc analysts commented, "Portola hosted an investor event at the American College of Cardiology (ACC) annual meeting. Data from betrixaban's APEX Phase III and AndexXa's ANNEXA-4 Phase IV trials were discussed. Investors were keenly focused on examining the APEX clinical data ahead of betrixaban's June PDUFA. While risk remains, we think approval is more likely than not. We remain at Outperform." (3/20/2017)
Who are some of Portola Pharmaceuticals' key competitors?
Some companies that are related to Portola Pharmaceuticals include Ionis Pharmaceuticals (IONS), Icon (ICLR), Covance (CVD), Galapagos (GLPG), United Therapeutics (UTHR), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), Anacor Pharmaceuticals (ANAC), FibroGen (FGEN), Syneos Health (SYNH), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), Shire Viropharma (VPHM), Ligand Pharmaceuticals (LGND), Global Blood Therapeutics (GBT) and Foundation Medicine (FMI).
Who are Portola Pharmaceuticals' key executives?
Portola Pharmaceuticals' management team includes the folowing people:
- Hollings C. Renton III, IndependentChairman of the Board (Age 70)
- William Lis, Chief Executive Officer, Director (Age 52)
- Mardi C. Dier, Chief Financial Officer, Executive Vice President (Age 53)
- John T. Curnutte M.D. Ph.D., Executive Vice President - Research & Development (Age 65)
- Tao Fu, Executive Vice President, Chief Commercial and Business officer (Age 45)
- John Lawrence, Senior Vice President, Chief Medical Officer
- Jeffrey W. Bird M.D. Ph.D., Independent Director (Age 56)
- Laura A. Brege, Independent Director (Age 59)
- Dennis M. Fenton Ph.D., Independent Director (Age 65)
- Charles J. Homcy M.D., Independent Director (Age 68)
Who owns Portola Pharmaceuticals stock?
Portola Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.20%), Kornitzer Capital Management Inc. KS (1.27%), Fred Alger Management Inc. (1.16%), Wells Fargo & Company MN (1.05%), Deutsche Bank AG (0.97%) and Geode Capital Management LLC (0.95%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.
Who sold Portola Pharmaceuticals stock? Who is selling Portola Pharmaceuticals stock?
Portola Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Two Sigma Investments LP, Guggenheim Capital LLC, Pinnacle Associates Ltd., Marcus Capital LLC, Alliancebernstein L.P. and Metropolitan Life Insurance Co. NY. Company insiders that have sold Portola Pharmaceuticals company stock in the last year include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals.
Who bought Portola Pharmaceuticals stock? Who is buying Portola Pharmaceuticals stock?
Portola Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., Two Sigma Advisers LP, Artal Group S.A., Amundi Pioneer Asset Management Inc., Kornitzer Capital Management Inc. KS, UBS Asset Management Americas Inc. and GW&K Investment Management LLC. View Insider Buying and Selling for Portola Pharmaceuticals.
How do I buy Portola Pharmaceuticals stock?
Shares of Portola Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Portola Pharmaceuticals' stock price today?
One share of Portola Pharmaceuticals stock can currently be purchased for approximately $48.22.
How big of a company is Portola Pharmaceuticals?
Portola Pharmaceuticals has a market capitalization of $3.15 billion and generates $35.50 million in revenue each year. The biopharmaceutical company earns $-269,040,000.00 in net income (profit) each year or ($4.32) on an earnings per share basis. Portola Pharmaceuticals employs 163 workers across the globe.
How can I contact Portola Pharmaceuticals?
Portola Pharmaceuticals' mailing address is 270 E Grand Ave Ste 22, SOUTH SAN FRANCISCO, CA 94080-4811, United States. The biopharmaceutical company can be reached via phone at +1-650-2446864 or via email at [email protected]
MarketBeat Community Rating for Portola Pharmaceuticals (PTLA)MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Portola Pharmaceuticals (NASDAQ:PTLA) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||2.88||2.88|
|Ratings Breakdown: ||0 Sell Rating(s)|
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$75.00||$75.00||$67.67||$65.83|
|Price Target Upside: ||42.53% upside||42.53% upside||33.86% upside||16.97% upside|
Portola Pharmaceuticals (NASDAQ:PTLA) Consensus Price Target History
Portola Pharmaceuticals (NASDAQ:PTLA) Analyst Ratings History
(Data available from 2/21/2016 forward)
Portola Pharmaceuticals (NASDAQ:PTLA) Earnings History and Estimates Chart
Portola Pharmaceuticals (NASDAQ PTLA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/6/2017||Q3 2017||($1.49)||($1.41)||$4.71 million||$3.83 million||View||N/A|
|8/9/2017||Q2 2017||($1.10)||($1.22)||$4.28 million||$3.79 million||View||Listen|
|5/8/2017||Q1 2017||($1.20)||($0.74)||$4.21 million||$5.12 million||View||Listen|
|2/28/2017||Q4 2016||($1.12)||($0.95)||$3.98 million||$13.70 million||View||Listen|
|11/7/2016||Q3||($1.10)||($1.64)||$4.10 million||$9.30 million||View||Listen|
|8/9/2016||Q216||($1.20)||($1.02)||$4.38 million||$4.23 million||View||Listen|
|5/5/2016||Q1||($1.06)||($1.15)||$7.91 million||$8.30 million||View||Listen|
|2/26/2016||Q415||($1.12)||($1.23)||$2.43 million||$4.40 million||View||Listen|
|11/9/2015||Q3 2015||($1.24)||($1.05)||$2.40 million||$2.91 million||View||N/A|
|8/4/2015||Q215||($1.07)||($1.12)||$2.30 million||$2.39 million||View||Listen|
|5/6/2015||Q115||($1.09)||($0.95)||$2.60 million||$2.36 million||View||Listen|
|3/2/2015||Q414||($0.90)||($0.82)||$2.40 million||$2.41 million||View||Listen|
|11/10/2014||Q314||($0.92)||($0.86)||$2.73 million||$2.40 million||View||Listen|
|8/6/2014||Q214||($0.79)||($0.76)||$2.44 million||$2.42 billion||View||Listen|
|5/12/2014||Q114||($0.72)||($0.75)||$1.81 million||$2.40 million||View||Listen|
|2/27/2014||Q4||($0.57)||($0.63)||$2.17 million||$2.10 million||View||Listen|
|11/5/2013||Q3 2013||($0.68)||($0.53)||$2.00 million||$2.77 million||View||N/A|
|8/15/2013||($0.72)||($1.47)||$2.00 million||$2.60 million||View||Listen|
Portola Pharmaceuticals (NASDAQ:PTLA) Earnings Estimates
2018 EPS Consensus Estimate: ($4.13)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Portola Pharmaceuticals (NASDAQ:PTLA)
No dividend announcements for this company have been tracked by MarketBeat.com
Portola Pharmaceuticals (NASDAQ PTLA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 86.45%
Portola Pharmaceuticals (NASDAQ PTLA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/15/2017||Henry Ward Wolff||Director||Sell||12,000||$47.00||$564,000.00|| |
|7/18/2017||John T. Curnutte||Insider||Sell||10,000||$65.00||$650,000.00|| |
|7/18/2017||Tao Fu||EVP||Sell||5,812||$65.00||$377,780.00|| |
|7/11/2017||Mardi Dier||VP||Sell||23,350||$60.00||$1,401,000.00|| |
|6/28/2017||William Lis||CEO||Sell||269,299||$55.43||$14,927,243.57|| |
|6/27/2017||Mardi Dier||VP||Sell||93,392||$55.46||$5,179,520.32|| |
|6/26/2017||John T. Curnutte||Insider||Sell||60,000||$57.88||$3,472,800.00|| |
|6/26/2017||Tao Fu||EVP||Sell||7,000||$57.14||$399,980.00|| |
|6/23/2017||Charles J. Homcy||Director||Sell||120,803||$53.06||$6,409,807.18|| |
|6/1/2017||(Mauritius) Pte Ltd Maxwell||Major Shareholder||Sell||1,700,000||$34.40||$58,480,000.00|| |
|6/1/2017||Jeffrey W Bird||Director||Buy||119,442||$31.85||$3,804,227.70||3,000|| |
|4/11/2017||William Lis||CEO||Sell||6,750||$36.06||$243,405.00||4,730|| |
|4/10/2017||Tao Fu||EVP||Sell||1,097||$36.97||$40,556.09|| |
|3/15/2017||Charles J. Homcy||Director||Sell||50,000||$40.06||$2,003,000.00|| |
|3/15/2017||Mardi Dier||VP||Sell||10,235||$40.02||$409,604.70|| |
|5/2/2016||William Lis||CEO||Sell||5,675||$23.86||$135,405.50||18,333|| |
|12/9/2015||Fullerton Management Pte Ltd||Major Shareholder||Buy||750,000||$48.00||$36,000,000.00|| |
|9/18/2015||Charles J. Homcy||Director||Sell||40,067||$56.25||$2,253,768.75|| |
|9/18/2015||Mardi Dier||CFO||Sell||8,912||$55.00||$490,160.00|| |
|7/15/2015||John T Curnutte||EVP||Sell||10,000||$50.00||$500,000.00|| |
|7/15/2015||William Lis||CEO||Sell||50,000||$50.00||$2,500,000.00|| |
|7/13/2015||Charles J Homcy||Director||Sell||50,000||$48.00||$2,400,000.00|| |
|7/2/2015||William Lis||CEO||Sell||15,000||$45.60||$684,000.00|| |
|7/1/2015||William Lis||CEO||Sell||30,000||$45.01||$1,350,300.00|| |
|6/30/2015||William Lis||CEO||Sell||15,000||$44.48||$667,200.00|| |
|6/29/2015||Charles J Homcy||Director||Sell||100,000||$43.78||$4,378,000.00|| |
|6/22/2015||John T Curnutte||EVP||Sell||10,000||$47.50||$475,000.00|| |
|6/16/2015||John T Curnutte||EVP||Sell||10,000||$45.00||$450,000.00|| |
|6/8/2015||Mardi Dier||CFO||Sell||16,119||$43.00||$693,117.00|| |
|5/29/2015||John T Curnutte||EVP||Sell||10,000||$42.50||$425,000.00|| |
|5/28/2015||John T Curnutte||EVP||Sell||10,000||$40.30||$403,000.00|| |
|5/27/2015||Mardi Dier||CFO||Sell||6,076||$41.00||$249,116.00|| |
|5/12/2015||Mardi Dier||CFO||Sell||13,290||$37.88||$503,425.20|| |
|5/11/2015||Hollings Renton||Director||Sell||10,520||$38.33||$403,231.60|| |
|5/11/2015||Mardi Dier||CFO||Sell||13,674||$38.21||$522,483.54|| |
|4/30/2015||William Lis||CEO||Sell||45,000||$35.60||$1,602,000.00|| |
|2/23/2015||Charles J Homcy||Director||Sell||20,000||$40.00||$800,000.00|| |
|2/23/2015||John T Curnutte||EVP||Sell||10,000||$40.00||$400,000.00|| |
|2/23/2015||Mardi Dier||CFO||Sell||5,692||$39.95||$227,395.40|| |
|2/18/2015||John T Curnutte||EVP||Sell||10,000||$37.50||$375,000.00|| |
|2/17/2015||Charles J Homcy||Director||Sell||20,000||$36.00||$720,000.00|| |
|2/17/2015||John T Curnutte||EVP||Sell||10,000||$35.00||$350,000.00|| |
|2/13/2015||Charles J Homcy||Director||Sell||20,000||$34.05||$681,000.00|| |
|2/13/2015||John T Curnutte||EVP||Sell||10,000||$32.50||$325,000.00|| |
|1/28/2015||Charles J Homcy||Director||Sell||19,700||$30.00||$591,000.00|| |
|1/20/2015||William Lis||CEO||Sell||20,000||$27.32||$546,400.00|| |
|1/16/2015||William Lis||CEO||Sell||20,000||$26.94||$538,800.00|| |
|11/25/2014||Mardi Dier||CFO||Sell||1,118||$28.23||$31,561.14|| |
|11/20/2014||William Lis||CEO||Sell||40,000||$26.95||$1,078,000.00|| |
|11/17/2014||William Lis||CEO||Sell||30,000||$26.69||$800,700.00|| |
|10/8/2014||(Mauritius) Pte Ltd Maxwell||Major Shareholder||Buy||1,600,000||$26.00||$41,600,000.00|| |
|8/25/2014||Mardi Dier||CFO||Sell||5,000||$26.26||$131,300.00|| |
|7/25/2014||Mardi Dier||CFO||Sell||5,000||$24.11||$120,550.00|| |
|7/3/2014||William Lis||CEO||Sell||30,000||$30.41||$912,300.00|| |
|6/30/2014||William Lis||CEO||Sell||10,000||$29.23||$292,300.00|| |
|6/25/2014||Mardi Dier||CFO||Sell||5,000||$28.52||$142,600.00|| |
|6/18/2014||John T Curnutte||EVP||Sell||30,000||$28.33||$849,900.00|| |
|6/18/2014||Mardi Dier||CFO||Sell||3,706||$29.95||$110,994.70|| |
|6/16/2014||John T Curnutte||EVP||Sell||10,000||$26.00||$260,000.00|| |
|6/10/2014||Nicholas Galakatos||Director||Sell||1,369||$23.36||$31,979.84|| |
|5/29/2014||Mardi Dier||CFO||Sell||5,000||$23.00||$115,000.00|| |
|5/27/2014||William Lis||CEO||Sell||30,000||$20.83||$624,900.00|| |
|5/21/2014||William Lis||CEO||Sell||10,000||$19.87||$198,700.00|| |
|5/16/2014||Jean Jacques Bienaime||Director||Sell||1,000||$22.03||$22,030.00||706|| |
|4/25/2014||Mardi Dier||CFO||Sell||5,000||$24.14||$120,700.00||24,824|| |
|3/25/2014||Mardi Dier||CFO||Sell||5,000||$25.69||$128,450.00||29,824|| |
|10/22/2013||Charles J Homcy||Director||Sell||95,962||$23.75||$2,279,097.50|| |
|5/28/2013||(Mauritius) Pte Ltd Maxwell||Major Shareholder||Buy||700,000||$14.50||$10,150,000.00|| |
Portola Pharmaceuticals (NASDAQ PTLA) News Headlines
Portola Pharmaceuticals (NASDAQ:PTLA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Portola Pharmaceuticals (NASDAQ:PTLA) Income Statement, Balance Sheet and Cash Flow Statement
Portola Pharmaceuticals (NASDAQ PTLA) Stock Chart for Wednesday, February, 21, 2018